Karen Walker
Direttore Tecnico/Scientifico/R&S presso KYVERNA THERAPEUTICS, INC.
Patrimonio netto: - $ in data 30/04/2024
Profilo
Karen Walker is currently the Chief Technology Officer at Kyverna Therapeutics, Inc. She is also a member of the Parenteral Drug Association, Alliance For Regenerative Medicine’s Foundation, and PDA ATMP Working Group.
Previously, she held the position of Vice President at Novartis, Inc. and Seagen Inc. Ms. Walker received her undergraduate degree from St. Olaf College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 01/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di Karen Walker
| Società | Posizione | Inizio |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/2021 |
| Alliance For Regenerative Medicine’S Foundation | Corporate Officer/Principal | - |
| Parenteral Drug Association | Corporate Officer/Principal | - |
Precedenti posizioni note di Karen Walker
| Società | Posizione | Fine |
|---|---|---|
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Corporate Officer/Principal | - |
| SEAGEN INC. | Corporate Officer/Principal | - |
Formazione di Karen Walker
| St. Olaf College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
| Parenteral Drug Association | |
| Alliance For Regenerative Medicine’S Foundation |
- Borsa valori
- Insiders
- Karen Walker
